BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-03-14; most recent amendment 2026-07-17.
Status change: Enrolling by Invitation → Active, Not Recruiting2021-12-17